Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1-ABL2 Fusion

10.1097/hs9.0000000000000193 ◽

2019 ◽

Vol 3 (3) ◽

pp. e193 ◽

Author(s):

Gauthier Decool ◽

Carine Domenech ◽

Nathalie Grardel ◽

Adriana Plesa ◽

Imelda Raczkiewicz ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Lymphoblastic Leukemia ◽

Inhibitor Therapy ◽

Cell Precursor ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion

Haematologica ◽

10.3324/haematol.2013.095372 ◽

2013 ◽

Vol 98 (11) ◽

pp. e146-e148 ◽

Author(s):

E. Lengline ◽

K. Beldjord ◽

H. Dombret ◽

J. Soulier ◽

N. Boissel ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Lymphoblastic Leukemia ◽

Inhibitor Therapy ◽

Cell Precursor ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1-ABL2 Fusion

10.1097/02014419-900000000-99911 ◽

2019 ◽

pp. 1

Author(s):

Gauthier Decool ◽

Carine Domenech ◽

Nathalie Grardel ◽

Adriana Plesa ◽

Imelda Raczkiewicz ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Lymphoblastic Leukemia ◽

Inhibitor Therapy ◽

Cell Precursor ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient With Refractory EBF1-PDGFRB–Positive Acute Lymphoblastic Leukemia

Journal of Clinical Oncology ◽

10.1200/jco.2012.47.6770 ◽

2013 ◽

Vol 31 (25) ◽

pp. e413-e416 ◽

Author(s):

Brent W. Weston ◽

Melissa A. Hayden ◽

Kathryn G. Roberts ◽

Susan Bowyer ◽

Johann Hsu ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Lymphoblastic Leukemia ◽

Inhibitor Therapy ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

Philadelphia chromosome-positive leukemia stem cells in acute lymphoblastic leukemia and tyrosine kinase inhibitor therapy

World Journal of Stem Cells ◽

10.4252/wjsc.v4.i6.44 ◽

2012 ◽

Vol 4 (6) ◽

pp. 44 ◽

Author(s):

Xavier Thomas

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Inhibitor Therapy ◽

Leukemia Stem Cells ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion

International Journal of Hematology ◽

10.1007/s12185-020-03006-5 ◽

2020 ◽

Author(s):

Shuki Oya ◽

Satoshi Morishige ◽

Hidetoshi Ozawa ◽

Kensuke Sasaki ◽

Yuichiro Semba ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Lymphoblastic Leukemia ◽

Inhibitor Therapy ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia

Leukemia Research ◽

10.1016/j.leukres.2019.02.009 ◽

2019 ◽

Vol 79 ◽

pp. 27-33 ◽

Author(s):

Amber C. King ◽

Jeremy J. Pappacena ◽

Martin S. Tallman ◽

Jae H. Park ◽

Mark B. Geyer

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Inhibitor Therapy ◽

Tyrosine Kinase Inhibitor Therapy ◽

Measurable Residual Disease

Download Full-text

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

Journal of Hematology & Oncology ◽

10.1186/s13045-020-00912-3 ◽

2020 ◽

Vol 13 (1) ◽

Author(s):

Xinhua Xiao ◽

Ping Liu ◽

Donghe Li ◽

Zhizhou Xia ◽

Peihong Wang ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Combination Therapy ◽

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Lymphoblastic Leukemia ◽

Kinase Inhibition ◽

Cell Acute Lymphoblastic Leukemia

Download Full-text

Abstract 4223: Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-Jun N-terminal kinase inhibition

10.1158/1538-7445.am2020-4223 ◽

2020 ◽

Author(s):

Xinhua Xiao ◽

Bo Jiao ◽

Ruibao Ren

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Combination Therapy ◽

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Lymphoblastic Leukemia ◽

Kinase Inhibition ◽

Cell Acute Lymphoblastic Leukemia

Download Full-text

BCR–ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy

Blood Cancer Journal ◽

10.1038/bcj.2011.26 ◽

2011 ◽

Vol 1 (7) ◽

pp. e30-e30 ◽

Author(s):

G Riva ◽

M Luppi ◽

C Quadrelli ◽

P Barozzi ◽

S Basso ◽

...

Keyword(s):

Bone Marrow ◽

T Cells ◽

Acute Lymphoblastic Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Second Generation ◽

Kinase Inhibitor ◽

Cytotoxic T Cells ◽

Lymphoblastic Leukemia ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

Faculty Opinions recommendation of Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1061886.541558 ◽

2007 ◽

Author(s):

Karen Anderson

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text